Outlier [Study As­sess­ment]

posted by NK – India, 2023-06-27 05:57 (166 d 01:02 ago) – Posting: # 23616
Views: 880

Dear All,

Please give your valuable inputs.

We have performed 2x2 fasting BE pivotal study for USFDA after seeing pilot study results.

We've noted following from pivotal study data,How to handle this subject’s data? Outlier? Can the regulatory accept the based on Cmax and AUC0-t results?

Can we select the time point manually for Kel calculation instead of best fit method by the tool?

Thanks & Regards

Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,822 posts in 4,786 threads, 1,633 registered users;
26 visitors (0 registered, 26 guests [including 6 identified bots]).
Forum time: 05:59 CET (Europe/Vienna)

A scientist’s aim in a discussion with his colleagues
is not to persuade, but to clarify.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz